News

Pharmabiz12h
Aspire Biopharma enrolls last patient in phase 1 trial of its oral transmucosal fast-acting high-dose aspirin formulation
Aspire Biopharma enrolls last patient in phase 1 trial of its oral transmucosal fast-acting high-dose aspirin formulation: Estero, Florida Thursday, June 26, 2025, 18:00 Hrs [IST] ...
Charlotte Observer2d
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - Charlotte Observer
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation ACCESS Newswire Updated June 24, 2025 8:41 AM ...
Miami Herald2d
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - Miami Herald
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation ACCESS Newswire Updated June 24, 2025 8:41 AM ...
Morningstar2d
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation | Morningstar
The Phase 1 clinical trial, which is being conducted in the United States, compares the pharmacokinetic and pharmacodynamic characteristics of normal healthy adult volunteers after the ...
Finanznachrichten3d
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - FinanzNachrichten.de
Enrollment Completed on Schedule; Topline Results Expected Mid Q3 2025 ESTERO, FL AND NEW YORK, NY / ACCESS Newswire / June 24, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or ...
BioSpace3d
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - BioSpace
The Phase 1 clinical trial, which is being conducted in the United States, compares the pharmacokinetic and pharmacodynamic characteristics of normal healthy adult volunteers after the administration ...
ahajournals.org2d
Erythrocyte Promotion of Platelet Reactivity Decreases the Effectiveness of Aspirin as an Antithrombotic Therapeutic Modality | Circulation - AHA/ASA Journals
Background—Aspirin (acetylsalicylic acid, ASA) ... The effect of intermediate-dose aspirin (200 to 300 mg) ... BMJ. 1994; 308:81–106. Crossref Medline Google Scholar; 3 Patrono C. Aspirin as an ...